This timely Second Edition reflects the mounting pressure on pharmaceutical companies to accelerate the new drug development and launch process, and the shift from developing small molecules to the growth of biopharmaceuticals. It meets the need for up-to-date and advanced information for drug preformulation and formulation, and addresses the current trends in the continually evolving pharmaceutical industry.Ideal for practitioners working in the pharmaceutical industry (including R&D scientists, technicians, and managers), as well as undergraduate and postgraduate courses in industrial pharmacy and pharmaceutical technology, this text addresses:candidate drug selection drug discovery and development preformulation predictions and drug selections product design to commercial dosage form biopharmaceutical support in formulation development and more

Mark Gibson, Bpharm, Ph.D., CChem, MRSC, MRpharmS, is responsible for product development of New Molecular Entities and New Product Opportunities at AstraZeneca RD Charnwood, Leicestershire, UK. His experience encompasses 25 years in the pharmaceutical industry, both as a bench scientist and a manager, at Cyanamid (Lederle), Fisons Pharmaceuticals, Astra Pharmaceuticals, and AstraZeneca. He has worked on a wide variety of dosage forms and routes of delivery, including inhalation, oral, nasal, opthalmic, parenteral, and transdermal, some of which have resulted in patents and marketable products. Dr Gibson is a member of the Royal Pharmaceutical Society, the Royal Society of Chemistry, the UK Academy of Pharmaceutical Sciences, and the Parenteral Drug Association.